drugset / Trial / NCT03780634
HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC
Phase 2
Withdrawn
Sun Yat-sen University
Guangzhou No.12 People's Hospital · collabKaiping Central Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of hepatic artery infusion chemotherapy (HAIC) combined with Programmed Cell Death Protein-1 (PD-1) antibody compared with HAIC plus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
Timeline
- Start
- 2019-04-01
- Primary completion
- 2020-12-01
- Completion
- 2021-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Comparator | Sorafenib | Small molecule | 400 mg | Oral |